A personalized approach to metabolic aspects of obesity

Mount Sinai Journal of Medicine

Volumn 77, Issue 5, 2010, Pages 499-510

  Brietzke, Stephen A ^a  

^a University of Missouri   (United States)

Author keywords

adiponectin; cardiovascular risk; dyslipidemia; insulin resistance; metabolic syndrome; visceral obesity

Indexed keywords

ACARBOSE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GEMFIBROZIL; INSULIN SENSITIZING AGENT; IRBESARTAN; METFORMIN; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELL SECRETION; CLINICAL TRIAL; DYSLIPIDEMIA; ENDOCRINE CELL; EXERCISE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SLEEP APNEA SYNDROME; VASOCONSTRICTION; WEIGHT REDUCTION;

DIABETES MELLITUS; ENERGY METABOLISM; HUMANS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 78449231987     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20206     Document Type: Review

References (78)

1. Bays HE., "Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009; 122 (suppl 1): S26 - S37.
2. Gable DR, Hurel SJ, Humphries SE., Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188: 231 - 244.
3. Reaven GM., Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595 - 1607.
4. Kaski JC, Elliott PM., Angina pectoris and normal coronary arteriograms: clinical presentation and hemodynamic characteristics. Am J Cardiol 1995; 76: 35D - 42D.
5. Ford ES, Giles WH, Mokdad AH., Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444 - 2449.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143.
7. Alberti KG, Zimmet PZ., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [see comment]. Diabet Med 1998; 15: 539 - 553.
8. Einhorn D, Reaven GM, Cobin RH, et al., American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237 - 252.
9. Alberti KG, Zimmet P, Shaw J., Metabolic syndrome'a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469 - 480.
10. Kahn R, Buse J, Ferrannini E, Stern M., The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289 - 2304. (Pubitemid 41242486)
11. Haffner SM., Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007; 120 (9 suppl 1): S10 - S17.
12. Abbasi F, Brown BW, Lamendola C, et al., Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937 - 943.
13. Wilson PW, D'Agostino RB, Parise H, et al., Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066 - 3072.
14. Sundstrom J, Riserus U, Byberg L, et al., Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878 - 882.
15. Wannamethee SGP, Shaper AGF, Lennon LM, Morris RWP., Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 2644 - 2650.
16. Najarian RM, Sullivan LM, Kannel WB, et al., Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006; 166: 106 - 111.
17. Lorenzo C, Williams K, Hunt KJ, Haffner SM., The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8 - 13.
18. Ozcan U, Cao Q, Yilmaz E, et al., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457 - 461.
19. Gregor MF, Hotamisligil GS., Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48: 1905 - 1914.
20. Anagnostis P, Athyros VG, Tziomalos K, et al., Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009; 94: 2692 - 2701.
21. Ahima RS., Adipose tissue as an endocrine organ. Obesity 2006; 14: 242 - 249.
22. Grassi G, Arenare F, Quarti-Trevano F, et al., Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis 2009; 52: 31 - 37.
23. Sowers JR, Whaley-Connell A, Epstein M., Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776 - 783.
24. Pittas AG, Joseph NA, Greenberg AS., Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447 - 452.
25. Chen H, Montagnani M, Funahashi T, et al., Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021 - 45026.
26. Ouchi N, Kihara S, Arita Y, et al., Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473 - 2476.
27. Fasshauer M, Kralisch S, Klier M, et al., Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045 - 1050.
28. Tataranni PA, Ortega E., A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes ? Diabetes 2005; 54: 917 - 927.
29. Koh KK, Han SH, Quon MJ., Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978 - 1985.
30. Jensen MD., Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93 (11 suppl 1): S57 - S63.
31. Ouchi N, Kihara S, Arita Y, et al., Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296 - 1301.
32. Han SH, Quon MJ, Kim JA, Koh KK., Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531 - 538.
33. Weyer C, Funahashi T, Tanaka S, et al., Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930 - 1935.
34. Iwashima Y, Katsuya T, Ishikawa K, et al., Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318 - 1323.
35. Adamczak M, Wiecek A, Funahashi T, et al., Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72 - 75.
36. Choi KM, Lee J, Lee KW, et al., The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004; 150: 715 - 718.
37. Higashiura K, Ura N, Ohata J, et al., Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol 2004; 61: 753 - 759.
38. Tschritter O, Fritsche A, Thamer C, et al., Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239 - 243.
39. Lindsay RS, Funahashi T, Hanson RL, et al., Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57.
40. Daimon M, Oizumi T, Saitoh T, et al., Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003; 26: 2015 - 2020.
41. Hulthe J, Hultén LM, Fagerberg B., Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1612 - 1614.
42. Matsubara M, Maruoka S, Katayose S., Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764 - 2769.
43. Pischon T, Girman CJ, Hotamisligil GS, et al., Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730 - 1737.
44. Kumada M, Kihara S, Sumitsuji S, et al., Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85 - 89.
45. Zoccali C, Mallamaci F, Tripepi G, et al., Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134 - 141. (Pubitemid 34042020)
46. Schulze MB, Shai I, Rimm EB, et al., Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534 - 539.
47. Okamoto Y, Kihara S, Funahashi T, et al., Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267 - 278.
48. Duncan BB, Schmidt MI, Pankow JS, et al., Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52: 1799 - 1805.
49. Hu FB, Meigs JB, Li TY, et al., Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693 - 700.
50. Esposito KM, Pontillo AM, Di Palo C, et al., Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799 - 1804.
51. Yang WS, Lee WJ, Funahashi T, et al., Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815 - 3819.
52. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393 - 403.
53. Tuomilehto J, Lindstrom J, Eriksson JG, et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343 - 1350. (Pubitemid 32378388)
54. Pan XR, Li GW, Hu YH, et al., Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537 - 544.
55. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096 - 1105.
56. Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med 2007; 357: 100 ]. N Engl J Med 2007; 356: 2457-2471.
57. Whelton SP, Chin A, Xin X, He J., Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493 - 503.
58. Kelley GA, Kelley KS, Tran ZV., Walking and resting blood pressure in adults: a meta-analysis. Prevent Med 2001; 33 (2 part 1): 120 - 127.
59. Chobanian AV, Bakris GL, Black HR, et al., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [see comment]. Hypertension 2003; 42: 1206 - 1252.
60. Sever PS, Dahlof B, Poulter NR, et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial'Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial [see comment]. Lancet 2003; 361: 1149 - 1158. (Pubitemid 36398384)
61. Manninen V, Tenkanen L, Koskinen P, et al., Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment [see comment]. Circulation 1992; 85: 37 - 45.
62. Reisin E, Jack AV., Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am 2009; 93: 733 - 751.
63. Wassmann S, Hilgers S, Laufs U, et al., Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208 - 1212.
64. Koh KK, Han SH, Chung WJ, et al., Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432 - 1435.
65. Gress TW, Nieto FJ, Shahar E, et al.,; The Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905 - 912.
66. Gurwitz JH, Bohn RL, Glynn RJ, et al., Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993; 118: 273 - 278.
67. Savage PJ, Pressel SL, Curb JD, et al., Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998; 158: 741 - 751.
68. Winkler K, Konrad T, Füllert S, et al., Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588 - 2594.
69. Raji A, Seely EW, Bekins SA, et al., Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172 - 178.
70. Hirose H, Kawai T, Yamamoto Y, et al., Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314 - 317.
71. Maeda N, Takahashi M, Funahashi T, et al., PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094 - 2099.
72. Yu JG, Javorschi S, Hevener AL, et al., The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968 - 2974.
73. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563 - 1574.
74. Koh KK, Son JW, Ahn JY, et al., Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004; 95: 185 - 191.
75. Freeman DJ, Norrie J, Sattar N, et al., Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357 - 362.
76. Koh KK, Han SH, Quon MJ, et al., Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005; 28: 1419 - 1424.
77. Buchanan TA, Xiang AH, Peters RK, et al., Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796 - 2803.
78. Chiasson JL, Josse RG, Gomis R, et al., Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072 - 2077.